Brivaracetam: 7 agencies, 2016–2026
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
Where brivaracetam met resistance it was usually narrowed rather than refused: 4 of 10 decisive outcomes were recommendations with restrictions, against 1 outright refusal.
Assessment has run over 10 years, from 2016 at PBAC (Australia) to 2026 at PBAC (Australia).
PBAC (Australia) changed its position: not recommended in 2016, recommended by 2019, after a resubmission.
No assessment is on file from PHARMAC (New Zealand), TLV (Sweden) and CIPM (Spain), each among the eight highest-volume agencies here.
The file is active: 4 of 16 records date from 2023 or later.
6 distinct indication wordings are recorded for brivaracetam by the agencies that label one in English (AWMSG, PBAC and SMC).
5 of these 16 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
PBAC (Australia) was first to assess brivaracetam, in 2016; HIRA (South Korea) did not open a file until 5 Mar 2026 — an unusually long tail of 9.7 years between the earliest and latest system to look at it.
The record arrives in waves: 6 separate years each carry two or more decisions, spread across 7 years in total.
Restriction is doing real work here: 4 of 10 decisive outcomes narrowed brivaracetam to a subgroup rather than accepting or refusing it outright, at AWMSG (Wales), HIRA (South Korea) and SMC (Scotland).
5 of the 7 agencies here assessed brivaracetam more than once, PBAC (Australia) most often at 5 entries — repeat review is the norm for this molecule rather than the exception.
7 of the 18 agencies in this archive hold a record for brivaracetam.
The full ledger for brivaracetam reads 5 recommended, 4 restricted, 3 no benefit and 1 advice, with 3 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| HIRA (South Korea) | 5 Mar 2026 | 16 세 이상의 뇌전증 환자에서 2 차성 전신발작을 동반하거나 동반하지 않는 부분 발작치료의 부가요법 | reimbursable only at the evaluated price | source |
| CHUIKYO (Japan) | 15 Aug 2024 | ブリィビアクト錠２５ｍｇ | listed on the NHI price list · 52 days after PMDA approval | source |
| HAS (France) | 14 Dec 2022 | Indication extension | SMR substantial · ASMR V | source |
| G-BA (Germany) | 1 Sep 2022 | Briviact (in Italy: Nubriveo) — benefit assessment §35a | added benefit: not proven | source |
| AWMSG (Wales) | 19 Jul 2022 | Adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adoles… | recommended with restrictions (licence extension for paediatric use) | source |
11 further decisions for brivaracetam, across 5 agencies, are not shown here. They include the most recent record on file, 2026 from PBAC (Australia); its outcome is in the subscriber dataset. They link to 6 further source documents.
Related molecules
- cannabidiol — same ATC class N03A — Antiepileptics
- levetiracetam — same ATC class N03A — Antiepileptics
- perampanel — same ATC class N03A — Antiepileptics
- lacosamide — same ATC class N03A — Antiepileptics
- zonisamide — same ATC class N03A — Antiepileptics
- rufinamide — same ATC class N03A — Antiepileptics
Coverage: 16 decisions for brivaracetam from 7 agencies, 2016 to 2026. Data to 7 Sep 2026. ATC class N03A — Antiepileptics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.